Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 9/20 | 0.46 |
| ▸ | MME | P08473 | 7/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23881976 | 0.92 | ECE1 (0.53) | ECE1MMEACE2CTSLCTSB | |
| SCHEMBL23881984 | 0.89 | CASP1 (0.47) | ECE1MMEACE2CTSLCTSB | |
| SCHEMBL23881665 | 0.81 | ECE1 (0.50) | ECE1MMEACE2CASP1 | |
| SCHEMBL23881969 | 0.79 | ACE2 (0.55) | ECE1MMEACE2 | |
| SCHEMBL23881801 | 0.77 | ACE2 (0.48) | ECE1MMEACE2 | |
| SCHEMBL10717446 | 0.77 | CTSB (0.52) | ECE1MMEACE2CTSLCTSB | |
| SCHEMBL23881979 | 0.77 | ACE2 (0.53) | ECE1MMEACE2 | |
| SCHEMBL10717382 | 0.77 | CTSL (0.52) | ECE1MMEACE2CTSLCTSB | |
| SCHEMBL23881872 | 0.77 | MGLL (0.51) | ECE1MMEACE2CASP1 | |
| SCHEMBL23881985 | 0.77 | ACE2 (0.53) | ECE1MMEACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309677-A1 | NOVEL AMINOPHOSPHINIC DERIVATIVES AS AMINOPEPTIDASE A INHIBITORS | COLLEGE DE FRANCE (FR) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309677-A1 | NOVEL AMINOPHOSPHINIC DERIVATIVES AS AMINOPEPTIDASE A INHIBITORS | ANPEP, DNPEP, ENPEP | ECE1 67/4885MME 24/4885ACE2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.